<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747678</url>
  </required_header>
  <id_info>
    <org_study_id>ahmed19782020</org_study_id>
    <nct_id>NCT04747678</nct_id>
  </id_info>
  <brief_title>Adverse Effects of Ivermectin Used in Egypt During COVID-19</brief_title>
  <official_title>Tolerability and Adverse Effects of Using Multiple Doses of Ivermectin in Egypt During Covid 19 Pandemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <brief_summary>
    <textblock>
      retrograde study of common and rare adverse effects of multiple doses of ivermectin used&#xD;
      during the coivd 19 pandemic in egypt&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ivermectin was used in Egypt during the pandemic of covid-19 and it was registered in the MOH&#xD;
      protocol that has been published in November 2020 the study will document the adverse effects&#xD;
      of many patients used ivermectin as aprophylaxis and as a treatment with multiple dose&#xD;
      regimens&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">February 3, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>all adverse effects will be collected from people used Ivermectin in between September 2020 to December 2020</measure>
    <time_frame>the data will be collected from February 2021 to march 2021</time_frame>
    <description>all data will be collected from retrospective manner as a retrospective study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all data will be arranged according to time and dose manner</measure>
    <time_frame>February to match 2021</time_frame>
    <description>data for each dose will be identified together</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <condition>Ivermectin Poisoning</condition>
  <condition>Drug Toxicity</condition>
  <condition>Drug Side Effect</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all healthy and diseased people who used ivermectin the last three months either as a&#xD;
        treatment or as a prophylaxis with mention of the doses used and the adverse effects&#xD;
        experienced during and after the usage&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all people used ivermectin as a treatment or as a prophylactic in covid 19 pandemic in&#xD;
             egypt with explained dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Ahmed Mansour</name>
      <address>
        <city>ShibÄ«n Al Kawm</city>
        <state>Menoufia</state>
        <zip>24222</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>ahmed mohamed esmat fahim mansour</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poisoning</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

